维升药业-B上半年研发支出同比增长19.8%,核心产品隆培生产激素预期四季度获BLA批准

格隆汇
Aug 27, 2025

格隆汇8月27日丨维升药业-B(02561.HK)公布中期业绩,2025年上半年,公司研发开支约为人民币4662.1万元,同比增长19.80%,期内亏损1.18亿元。截至2025年6月30日,现金及现金等价物为人民币8.06亿元,较2024年底增加了人民币6.02亿元。此外,公司近期已获得人民币3.00亿元的无担保银行授信,将有助于公司提高资金的使用效率和财务灵活性。公司预计在2026年及以后实现...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10